VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGLAgilon Health, Inc.
$90.53$1.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. AGL
  4. Financial Ratios

Agilon Health, Inc. (AGL) Financial Ratios

Latest Ratios: P/E Ratio -15.1x · EV/EBITDA N/A · ROE -135.6%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

AGL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$1.5B$285M$781M$5.1B$6.6B$10.1B——
Enterprise Value$1.4B$148M$631M$5.1B$6.2B$9.1B——
P/E Ratio →-15.10———————
P/S Ratio0.250.050.131.192.766.62——
P/B Ratio11.832.251.667.766.339.22——
P/FCF————————
P/OCF————————

P/E links to full P/E history page with 30-year chart

AGL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—0.020.101.172.595.96——
EV / EBITDA————————
EV / EBIT————————
EV / FCF————————

AGL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin-3.2%-3.2%0.1%1.6%4.7%4.3%7.7%3.6%
Operating Margin-7.1%-7.1%-4.8%-5.4%-4.4%-24.5%-4.7%-13.4%
Net Profit Margin-6.8%-6.8%-4.3%-6.1%-4.5%-26.7%-4.9%-35.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-135.6%-135.6%-46.0%-30.9%-10.0%-100.8%——
ROA-27.0%-27.0%-15.0%-15.3%-6.5%-40.0%-14.1%-70.2%
ROIC-203.2%-203.2%-47.6%-28.4%-21.8%-289.6%——
ROCE-108.4%-108.4%-43.4%-24.1%-8.8%-52.8%-29.6%-52.5%

AGL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.290.290.090.080.050.05——
Debt / EBITDA————————
Net Debt / Equity—-1.08-0.32-0.09-0.40-0.91——
Net Debt / EBITDA————————
Debt / FCF————————
Interest Coverage-59.85-59.85-39.28-28.21-19.22-61.31-6.66-11.65

Net cash position: cash ($174M) exceeds total debt ($37M)

AGL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio1.021.021.271.512.713.831.101.23
Quick Ratio1.021.021.271.512.713.831.101.23
Cash Ratio0.260.260.350.511.642.960.400.62
Asset Turnover—4.673.502.481.410.962.731.97
Inventory Turnover————————
Days Sales Outstanding—41.4561.2579.7075.2570.3943.3142.85

AGL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————————
FCF Yield————————
Buyback Yield0.2%1.1%0.0%3.9%0.0%0.0%——
Total Shareholder Yield0.2%1.1%0.0%3.9%0.0%0.0%——
Shares Outstanding—$17M$16M$16M$16M$15M$15M$15M

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent negative unit economics

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Valuation Rests on Book Value Not Earnings

As reported in AGL's filings, the P/E of -4.63 is not meaningful given losses, leaving P/B of 14.82 and P/S of 0.32 as the only usable multiples, and the wide gap between them signals that the market is pricing future recovery rather than current earnings power.

A negative P/E means earnings-based comparison is unavailable, so the analysis relies on sales and book value multiples. The P/S of 0.32 appears low against peers with positive margins, which may reflect the market discounting revenue that is not converting into profit. The P/B of 14.82 is elevated relative to a shrinking equity base, suggesting investors may be assigning value to the 20-year physician contract moat rather than to tangible book value, an assumption that warrants further investigation.

Margins Recovering But Remain Below Breakeven

Based on AGL's reported figures, gross margin improved to 6.4% and operating margin to 1.6% in Q3 2026 from deeply negative levels in late 2025, yet net margin of 2.3% rests on a single quarter that is not yet confirmed as durable.

Operating margin remains thin and is below the 4.1% to 6.2% gross margin range seen in earlier quarters, indicating SG&A still absorbs most gross profit. Compared with peers such as Elevance at 2.8% net margin and Molina at 1.0%, AGL's latest quarter is competitive, but its ten-quarter history of sharp reversals suggests the recovery may reflect timing of medical cost recognition rather than structural improvement. Investors should monitor whether gross margin holds above zero across several consecutive quarters.

Returns Swing Sharply With Thin Equity Base

According to reported ratios, ROIC moved from -144.8% in Q4 2025 to 12.3% in Q3 2026, but this swing is amplified by shrinking invested capital and a negative retained earnings balance rather than reflecting a steady compounding trajectory.

Return metrics appear distorted by the equity base, which fell sharply before partially rebounding, so percentage returns overstate the quality of the latest print. ROE of 13.7% against peers like Elevance at 11.6% looks favorable, but investors should weigh this against the Q3 2026 equity increase that may reflect non-operating items. Sustained ROIC above the cost of capital would require several more quarters of positive operating income before the trend can be treated as compounding.

Low Debt Load Masks Operating Fragility

Based on AGL's reported figures, debt-to-equity of 0.12 and debt-to-EBITDA of 1.08 appear conservative, yet interest coverage swung from -108.30x to 23.31x across recent quarters, indicating coverage is driven by volatile earnings rather than a stable cushion.

The low absolute debt level, roughly $33M to $46M, limits refinancing pressure and suggests minimal exposure to rising rates. However, interest coverage metrics are unreliable as a comfort indicator because the denominator, operating income, has been negative for much of the period. Investors should treat the current leverage profile as adequate on paper while monitoring whether coverage stabilizes above a meaningful threshold.

Misapplied Ratio Obscures Medical Cost Reality

The P/B ratio is most commonly misapplied to AGL, as its 14.82 level and shrinking book value obscure whether the 20-year contract base provides durable economic value versus intangible goodwill that may not be recoverable.

Applying P/B to a physician enablement platform treats goodwill and contract intangibles as equivalent to tangible assets, which may overstate the cushion available to shareholders. A more informative alternative is medical margin per member, which isolates the spread between capitation revenue and medical claims before overhead. Investors should weigh this unit economic measure more heavily than book value multiples when assessing whether the business model is improving.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open AGL Terminal

AGL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AGL — Frequently Asked Questions

Quick answers to the most common questions about buying AGL stock.

What is Agilon Health, Inc.'s P/E ratio?

Agilon Health, Inc.'s current P/E ratio is -15.1x. This places it at the 50th percentile of its historical range.

What is Agilon Health, Inc.'s ROE?

Agilon Health, Inc.'s return on equity (ROE) is -135.6%. The historical average is -64.6%.

Is AGL stock overvalued?

Based on historical data, Agilon Health, Inc. is trading at a P/E of -15.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Agilon Health, Inc.'s profit margins?

Agilon Health, Inc. has -3.2% gross margin and -7.1% operating margin.